AIM ImmunoTech Announces Publication of Journal Article On the Positive Effect of Ampligen and Interferon-Alpha on Tumor Growth [Yahoo! Finance]
AIM ImmunoTech Inc. (AIM)
Company Research
Source: Yahoo! Finance
OCALA, Fla., Sept. 22, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that the Journal for ImmunoTherapy of Cancer JITC ) has published a new peer-reviewed article providing evidence of a positive combination effect of AIM's drug Ampligen and interferon-alpha on tumor growth and subsequent subject survival. The paper concluded that the ability of systemic chemokine modulation to eliminate the PD-1-resistance of cold tumors indicates that intratumoral cytotoxic t-lymphocyte accumulation, rather than tumor immunogenicity, is the key factor limiting the therapeutic effectiveness of immune checkpoint inhibitors. These data suggest a broad therapeutic potential of tumor microenvironment reprogramming strategies. The article, titled " Synergy between TLR3-ligand and IFN-a in the transient sensitization of ‘Cold' tumors to PD-1 blockade and the induction of systemic immunity ," was published in JITC on September 18. About AIM
Show less
Read more
Impact Snapshot
Event Time:
AIM
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AIM alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AIM alerts
High impacting AIM ImmunoTech Inc. news events
Weekly update
A roundup of the hottest topics
AIM
News
- AIM ImmunoTech to Participate in Live ‘Fireside' Chat on Virtual Investor Closing Bell Series [Yahoo! Finance]Yahoo! Finance
- AIM ImmunoTech to Participate in Live ‘Fireside’ Chat on Virtual Investor Closing Bell SeriesGlobeNewswire
- AIM ImmunoTech GAAP EPS of -$1.57 misses by $0.59 [Seeking Alpha]Seeking Alpha
- AIM ImmunoTech Reports Third Quarter 2025 Financial Results and Highlights Continued Progress Across Pipeline with Strategic Focus on Pancreatic Cancer Clinical ProgramGlobeNewswire
- AIM ImmunoTech Details New UPMC Abstract on Completed Clinical Trial Involving Ampligen's Synergistic Potential in the Treatment of Advanced Recurrent Ovarian Cancer [Yahoo! Finance]Yahoo! Finance
AIM
Sec Filings
- 11/19/25 - Form 8-K
- 11/17/25 - Form 10-Q
- 11/17/25 - Form NT
- AIM's page on the SEC website